A Medicinal Cannabis Company That's Conducting Cli
Post# of 4861
(Total Views: 183)
Posted On: 05/27/2020 5:20:16 PM
A Medicinal Cannabis Company That's Conducting Clinical Research On Autism, Insomnia, And More....
May 27, 2020 9:57am
Zelira Therapeutics LTD (OTCQB: ZLDAF), a therapeutic medicinal cannabis company, is developing clinically validated cannabis products for the treatment of various medical conditions.
Chairman of Zelira, Osagie Imasogie, will be presenting at the event, along with Managing Director ex USA, Dr. Richard Hopkins.
“The world at large is increasingly accepting as conventional wisdom that cannabis really is a diverse and vital element of natural medicine. The list of scientifically legitimized medical applications of cannabis to treat some of our most debilitating health issues continues to grow—but there remain many mysteries of how and why,” said Imasogie. “In order to most effectively treat patients, more and expanded research must go hand-in-hand with expanded access.”
The Need For Clinical Testing
Zelira Therapeutics is focused on bringing clinical testing to the cannabis industry. This intensive research is becoming increasingly important as the widespread acceptance of cannabis continues to grow.
In their pursuit of cannabis-based clinical research, Zelira has launched two proprietary formulations under the HOPE brand focused on symptoms associated with Autism Spectrum Disorder, currently available in Pennsylvania, and soon to launch in Louisiana and other global markets.
Zelira has also announced results and is set to launch the world’s first cannabis-based treatment for insomnia later this year.
“Just last month we completed the world's first clinical trials using cannabis for the treatment of insomnia. This was a clinically validated (randomized, double-blind, cross-over design) study that found Zelira’s cannabinoid-based insomnia medication ZLT-101 met its primary and secondary endpoints for safety and efficacy,” said Imasogie.
The company’s current research initiatives are being held both in Australia and the United States. This research focuses on insomnia, autism, and opioid reduction; pre-clinical research examining the effect of cannabinoids in breast, brain, and pancreatic cancer; and research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
“Zelira is more focused than ever to deliver clinically validated, safe and effective medicine to patients of all ages in the United States and the world,” said Hopkins.
Source: Benzinga news letter
May 27, 2020 9:57am
Zelira Therapeutics LTD (OTCQB: ZLDAF), a therapeutic medicinal cannabis company, is developing clinically validated cannabis products for the treatment of various medical conditions.
Chairman of Zelira, Osagie Imasogie, will be presenting at the event, along with Managing Director ex USA, Dr. Richard Hopkins.
“The world at large is increasingly accepting as conventional wisdom that cannabis really is a diverse and vital element of natural medicine. The list of scientifically legitimized medical applications of cannabis to treat some of our most debilitating health issues continues to grow—but there remain many mysteries of how and why,” said Imasogie. “In order to most effectively treat patients, more and expanded research must go hand-in-hand with expanded access.”
The Need For Clinical Testing
Zelira Therapeutics is focused on bringing clinical testing to the cannabis industry. This intensive research is becoming increasingly important as the widespread acceptance of cannabis continues to grow.
In their pursuit of cannabis-based clinical research, Zelira has launched two proprietary formulations under the HOPE brand focused on symptoms associated with Autism Spectrum Disorder, currently available in Pennsylvania, and soon to launch in Louisiana and other global markets.
Zelira has also announced results and is set to launch the world’s first cannabis-based treatment for insomnia later this year.
“Just last month we completed the world's first clinical trials using cannabis for the treatment of insomnia. This was a clinically validated (randomized, double-blind, cross-over design) study that found Zelira’s cannabinoid-based insomnia medication ZLT-101 met its primary and secondary endpoints for safety and efficacy,” said Imasogie.
The company’s current research initiatives are being held both in Australia and the United States. This research focuses on insomnia, autism, and opioid reduction; pre-clinical research examining the effect of cannabinoids in breast, brain, and pancreatic cancer; and research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
“Zelira is more focused than ever to deliver clinically validated, safe and effective medicine to patients of all ages in the United States and the world,” said Hopkins.
Source: Benzinga news letter
(2)
(0)